Should I buy Cochlear stock in Australia in 2025?

Is it the right time to buy Cochlear?

Last update: 4 July 2025
CochlearCochlear
0 Commission
Best Brokers in 2025
4.5
hellosafe-logoScore
CochlearCochlear
4.5
hellosafe-logoScore
P. Laurore
P. LauroreFinance expert

Cochlear Limited (ASX: COH), a flagship name in Australia’s healthcare and medical devices sector, currently trades at approximately AUD 301.39 with a recent average daily trading volume of just under 200,000 shares. The company’s fiscal 2024 results demonstrated robust momentum, with revenue increasing 15.47% and net income up 18.7% on the back of new product launches and solid global demand. One notable development this year is the launch of the Nucleus Nexa System, reinforcing Cochlear’s innovation credentials and its potential for future growth across both developed and emerging markets. Despite a modest pullback from last year’s highs and a premium valuation, market sentiment remains notably constructive—evident in persistent Buy signals across key technical indicators and strong institutional conviction. The consensus among 13 respected national and international banks points toward a target price of AUD 391.81. Supported by a resilient balance sheet, low debt, and leadership in a market benefitting from aging populations, Cochlear stands out in the medical devices landscape. With technicals and fundamentals aligning, investors may see compelling long-term potential in this ASX leader.

  • Global market leader with 60% share in cochlear implants.
  • Strong revenue and net income growth in FY2024.
  • Robust innovation pipeline, highlighted by Nucleus Nexa launch.
  • Resilient balance sheet and disciplined capital management.
  • Consistent dividends with a 1.43% yield and solid cash flow.
  • Valuation remains elevated with a P/E over 50, requiring sustained growth.
  • Growth in developed markets becoming more challenging due to market maturity.
CochlearCochlear
0 Commission
Best Brokers in 2025
4.5
hellosafe-logoScore
CochlearCochlear
4.5
hellosafe-logoScore
  • Global market leader with 60% share in cochlear implants.
  • Strong revenue and net income growth in FY2024.
  • Robust innovation pipeline, highlighted by Nucleus Nexa launch.
  • Resilient balance sheet and disciplined capital management.
  • Consistent dividends with a 1.43% yield and solid cash flow.

Is it the right time to buy Cochlear?

Last update: 4 July 2025
P. Laurore
P. LauroreFinance expert
  • Global market leader with 60% share in cochlear implants.
  • Strong revenue and net income growth in FY2024.
  • Robust innovation pipeline, highlighted by Nucleus Nexa launch.
  • Resilient balance sheet and disciplined capital management.
  • Consistent dividends with a 1.43% yield and solid cash flow.
  • Valuation remains elevated with a P/E over 50, requiring sustained growth.
  • Growth in developed markets becoming more challenging due to market maturity.
CochlearCochlear
0 Commission
Best Brokers in 2025
4.5
hellosafe-logoScore
CochlearCochlear
4.5
hellosafe-logoScore
  • Global market leader with 60% share in cochlear implants.
  • Strong revenue and net income growth in FY2024.
  • Robust innovation pipeline, highlighted by Nucleus Nexa launch.
  • Resilient balance sheet and disciplined capital management.
  • Consistent dividends with a 1.43% yield and solid cash flow.
Cochlear Limited (ASX: COH), a flagship name in Australia’s healthcare and medical devices sector, currently trades at approximately AUD 301.39 with a recent average daily trading volume of just under 200,000 shares. The company’s fiscal 2024 results demonstrated robust momentum, with revenue increasing 15.47% and net income up 18.7% on the back of new product launches and solid global demand. One notable development this year is the launch of the Nucleus Nexa System, reinforcing Cochlear’s innovation credentials and its potential for future growth across both developed and emerging markets. Despite a modest pullback from last year’s highs and a premium valuation, market sentiment remains notably constructive—evident in persistent Buy signals across key technical indicators and strong institutional conviction. The consensus among 13 respected national and international banks points toward a target price of AUD 391.81. Supported by a resilient balance sheet, low debt, and leadership in a market benefitting from aging populations, Cochlear stands out in the medical devices landscape. With technicals and fundamentals aligning, investors may see compelling long-term potential in this ASX leader.
Table of Contents
  • What is Cochlear?
  • What is the price of Cochlear stock?
  • Our full analysis of the Cochlear stock
  • How to buy Cochlear stock in Australia?
  • Our 7 tips for buying Cochlear stock
  • The latest news about Cochlear
  • FAQ
icon

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Cochlear for over three years. Every month, hundreds of thousands of users in Australia trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, paid by Cochlear.

Check out the best brokers in Australia!Compare brokers

What is Cochlear?

IndicatorValueAnalysis
🏳️ NationalityAustraliaAustralian leader in hearing implant solutions with global reach.
💼 MarketASX (Australian Securities Exchange)Listed on ASX, widely held by retail and institutional investors.
🏛️ ISIN codeAU000000COH5Provides international investors with secure identification.
👤 CEODig HowittDig Howitt has led Cochlear’s global expansion since 2018.
🏢 Market cap19.71 billion AUDHigh market cap reflects its global dominance and investor trust.
📈 Revenue2.24 billion AUD (FY2024)Strong annual growth, benefiting from increasing implant demand.
💹 EBITDANot separately disclosed (Strong operational performance)Operational efficiency supports margins and ongoing innovation.
📊 P/E Ratio (Price/Earnings)53.44High P/E suggests strong future growth expectations but premium pricing.
🏳️ Nationality
Value
Australia
Analysis
Australian leader in hearing implant solutions with global reach.
💼 Market
Value
ASX (Australian Securities Exchange)
Analysis
Listed on ASX, widely held by retail and institutional investors.
🏛️ ISIN code
Value
AU000000COH5
Analysis
Provides international investors with secure identification.
👤 CEO
Value
Dig Howitt
Analysis
Dig Howitt has led Cochlear’s global expansion since 2018.
🏢 Market cap
Value
19.71 billion AUD
Analysis
High market cap reflects its global dominance and investor trust.
📈 Revenue
Value
2.24 billion AUD (FY2024)
Analysis
Strong annual growth, benefiting from increasing implant demand.
💹 EBITDA
Value
Not separately disclosed (Strong operational performance)
Analysis
Operational efficiency supports margins and ongoing innovation.
📊 P/E Ratio (Price/Earnings)
Value
53.44
Analysis
High P/E suggests strong future growth expectations but premium pricing.

What is the price of Cochlear stock?

The price of Cochlear stock is rising this week. Cochlear shares are currently trading at 301.39 AUD, down by 0.26 AUD over the last 24 hours, but up 1.42% for the week. The company has a market capitalisation of 19.71 billion AUD and an average three-month trading volume of 199,210 shares. With a P/E ratio of 53.44, a dividend yield of 1.43%, and a stock beta of 0.40, Cochlear combines robust sector leadership with relatively low volatility. This strong performance suggests a favourable outlook and continued investor confidence in Australia’s healthcare sector.

Our full analysis of the Cochlear stock

We have examined Cochlear's latest financial results and evaluated its stock performance across the past three years, integrating financial metrics, technical patterns, institutional market data, and the evolving competitive landscape through proprietary analytical methods. This comprehensive review highlights key developments and market dynamics shaping the outlook for Australia's healthcare technology leader. So, why might Cochlear stock once again become a strategic entry point into the fast-growing medtech sector in 2025?

Recent performance and market context

Cochlear has demonstrated exceptional resilience and adaptability, with a current share price of 301.39 AUD, reflecting a robust recovery within its 52-week range of 246.14 to 350.31 AUD. Over the past week, the stock rose 1.42%, offering a year-to-date advance of 3.97%—an encouraging pace despite temporary macro headwinds seen in the broader ASX healthcare segment. Market capitalisation stands at an impressive 19.71 billion AUD, making Cochlear one of the sector’s most influential players. Recent half-year results exceeded analyst expectations, underpinned by revenue of 1.17 billion AUD and net profit of 205.1 million AUD. Importantly, the company continues to benefit from global megatrends such as population ageing, rising cases of hearing loss, and a renewed focus on innovation in medical technology—factors driving persistent demand for implantable hearing solutions.

Technical analysis

Cochlear’s technical landscape offers several reasons for optimism. The RSI (14-day) is currently positioned at 50.55, signalling neutrality but poised for upward movement should momentum accelerate. The MACD, resting at 0.24, issues a subtle buy signal, which is confirmed by a bullish stochastic RSI (56.96), pointing to underlying strength. Notably, all key moving averages—20-day (287.28 AUD), 50-day (276.61 AUD), 100-day (272.26 AUD), and 200-day (284.21 AUD)—cluster near or below the current price, supporting a positive short- and medium-term trend. Technically, the share has established reliable support in the 276–280 AUD range and faces moderate resistance at the 350 AUD level. Taken together, these indicators form the foundation for a potential continuation of the current bullish phase, giving market participants the technical clarity to build positions with confidence.

Fundamental analysis

At the fundamental level, Cochlear offers a combination of sustainable revenue growth, robust profitability, and strong balance sheet characteristics. For FY2024, revenue climbed to 2.24 billion AUD (+15.47% YoY) and net income surged by 18.7% to 356.8 million AUD. The company translates its earnings into healthy returns on equity (20.31%) and a sector-leading profit margin of 16.05%, underscoring its worldwide market leadership. The forward P/E of 44.84 and trailing P/E of 53.44 reflect investor willingness to pay a premium for its market dominance and growth potential, a sentiment mirrored by a price/sales ratio of 8.56. While premium valuations prompt careful consideration, they are justified by several lasting structural strengths:

  • Technological innovation with significant, continuous R&D prioritisation
  • A dominant 60% global market share in cochlear implants
  • Powerful brand equity and consistent leadership in advanced product development
  • Resilient demand profile, especially in mature markets and among ageing populations
  • A prudent, growth-supportive capital structure, with a low debt-to-equity ratio of 13.2% and a 383.1 million AUD cash cushion

Moreover, recurring revenue from services, upgrades, and expanding aftermarket solutions adds defensiveness and greater predictability to future cash flows.

Volume and liquidity

Strong market confidence in Cochlear is clearly demonstrated by consistent trading activity, with an average three-month daily volume of 199,210 shares. This liquidity ensures smooth trade execution and dynamic price discovery, making the stock a reliable choice for both institutional and sophisticated retail investors. The substantial free float further supports Cochlear’s robust valuation profile, providing flexibility for investors to build or adjust positions without undue market impact.

Catalysts and positive outlook

Looking ahead, several key catalysts propel Cochlear’s sustained growth potential:

  • Product innovation: Launch of the Nucleus Nexa system showcases leadership in next-generation implant technology.
  • Geographic expansion: Strong growth in high-potential emerging markets and further penetration in developed regions.
  • Favourable demographics: Global ageing trends and increased screening for hearing loss are expanding Cochlear’s addressable market.
  • Strategic investments: Recent stake in Nyxoah will drive growth beyond hearing restoration, notably in sleep apnoea solutions.
  • Sustainability and ESG focus: Environmental, social, and governance (ESG) initiatives position the company attractively for a growing base of global asset managers.

The industry’s regulatory backdrop remains conducive to medical device innovation, and market forecasts indicate the cochlear implant sector is set to expand to over 4.7 billion USD by 2030. In addition, rising public and private healthcare spending worldwide further enhances sector tailwinds.

Investment strategies

Cochlear’s present positioning offers distinct advantages for various investor profiles:

  • Short-term traders might capitalise on momentum-building patterns above all key moving averages, looking for a technical breakout towards the 350 AUD resistance level.
  • Medium-term investors benefit from a steady earnings profile, increased dividend (1.43% yield), and the positive flow of company news around product launches and partnership announcements.
  • Long-term holders are well placed to capture compounding returns from demographic shifts, technological leadership, and broadening recurring revenue streams as the company expands internationally.

Strategically, entries near strong technical support or ahead of major product cycles can provide ideal risk-reward trade-offs. Investors may also consider scaling in at current valuations, especially with evidence of increasing volumes and improving sentiment after a period of range-bound trading.

Is it the right time to buy Cochlear?

Cochlear’s blend of sustainable revenue growth, compelling innovation, and dominant market share supports a powerful case for renewed investor interest at prevailing levels. With broad-based sector tailwinds, new product momentum, rising dividend streams, and strong fundamentals, the stock appears well positioned to deliver attractive performance in 2025 and beyond. The fundamentals justify a fresh look at Cochlear for portfolios seeking defensive growth and participation in the dynamic medtech space. The stock may be entering a new bullish phase, and for those prepared to take the long view, Cochlear seems to represent an excellent opportunity to capture value in an expanding segment of the healthcare sector.

How to buy Cochlear stock in Australia?

Buying Cochlear stock online is both straightforward and secure when you use a regulated Australian broker. Investors can choose between buying shares directly (spot buying) or trading via CFDs (Contracts for Difference), depending on their objectives and risk profile. Each method has its benefits, and you’ll find a detailed broker comparison further down the page to help you make your choice.

Spot buying

A cash purchase gives you direct ownership of Cochlear shares. Usually, brokers charge a fixed commission per order—typically around $5 to $10 AUD for each trade. With spot buying, you may also receive any dividends Cochlear pays out.

icon

Gain scenario

If the Cochlear share price is $301.39 AUD, you can buy around 3 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading lets you speculate on Cochlear's share price movements, without owning the underlying shares. You can use leverage, increasing both your exposure and your risk. Common fees include the spread (the difference between buy and sell price) and overnight financing for positions held longer than a day.

icon

Example of a gain with a leveraged CFD

You open a CFD position on Cochlear shares, with 5x leverage.

This gives you a market exposure of $5,000.

✔️ Gain scenario:

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before getting started, it’s wise to compare brokers’ fees, trading platforms, and account conditions—see our broker comparison tool further down this page. Remember, the best method depends on your investment goals, whether you prefer taking direct ownership or want to actively trade price movements with leverage.

Check out the best brokers in Australia!Compare brokers

Our 7 tips for buying Cochlear stock

📊 Step📝 Specific tip for Cochlear
Analyze the marketReview the strong healthcare sector trends and Cochlear’s leadership in the Australian medical devices market to assess current opportunity.
Choose the right trading platformSelect an ASX-regulated broker with competitive fees and robust research access for Cochlear stock purchases.
Define your investment budgetDecide how much you can invest in Cochlear, balancing your exposure given its premium valuation and diversifying alongside other sectors.
Choose a strategy (short or long term)Consider a long-term approach to benefit from Cochlear’s innovation pipeline and solid global demand outlook.
Monitor news and financial resultsStay updated on Cochlear’s earnings releases and R&D news, as both significantly impact investor sentiment in Australia.
Use risk management toolsUse stop-loss and limit orders to manage risks, as Cochlear’s price can fluctuate with market sentiment or sector news.
Sell at the right timePlan exits around technical price peaks or before major results announcements to maximise potential returns on Cochlear.
Analyze the market
📝 Specific tip for Cochlear
Review the strong healthcare sector trends and Cochlear’s leadership in the Australian medical devices market to assess current opportunity.
Choose the right trading platform
📝 Specific tip for Cochlear
Select an ASX-regulated broker with competitive fees and robust research access for Cochlear stock purchases.
Define your investment budget
📝 Specific tip for Cochlear
Decide how much you can invest in Cochlear, balancing your exposure given its premium valuation and diversifying alongside other sectors.
Choose a strategy (short or long term)
📝 Specific tip for Cochlear
Consider a long-term approach to benefit from Cochlear’s innovation pipeline and solid global demand outlook.
Monitor news and financial results
📝 Specific tip for Cochlear
Stay updated on Cochlear’s earnings releases and R&D news, as both significantly impact investor sentiment in Australia.
Use risk management tools
📝 Specific tip for Cochlear
Use stop-loss and limit orders to manage risks, as Cochlear’s price can fluctuate with market sentiment or sector news.
Sell at the right time
📝 Specific tip for Cochlear
Plan exits around technical price peaks or before major results announcements to maximise potential returns on Cochlear.

The latest news about Cochlear

Cochlear shares have gained 1.42% in the past week, outperforming the broader ASX200 Health Care sector. This positive short-term performance reflects increasing confidence among Australian investors in the company’s global market leadership, stable earnings, and consistent product innovation, making Cochlear attractive for fund flows into the sector.

Recent technical indicators show a decisive “Strong Buy” signal for Cochlear, with all key moving averages trending bullish. Across the 20-, 50-, 100-, and 200-day moving averages, Cochlear demonstrates robust price support above $284 AUD, reinforced by an overall technical rating of 11 Buy signals to 1 Sell, suggesting a favourable momentum for medium-term investors.

The company confirmed another period of financial outperformance with results exceeding analyst expectations in H1 FY2025. Revenue increased to $1.17 billion AUD and net income reached $205.1 million, highlighting Cochlear’s continuous operational strength and its success in capturing demand for implantable hearing solutions both domestically and abroad.

Cochlear’s market leadership is reinforced by its innovation pipeline, notably the recent launch of the Nucleus Nexa System. This next-generation product underlines the group’s commitment to R&D and strengthens its competitive position in Australia’s medical devices market, offering a clear growth catalyst as healthcare technology demand rises.

The stock maintains high liquidity and is supported by healthy trading volumes, enhancing its appeal to Australian institutional investors. With an average daily volume of nearly 200,000 shares and a market capitalisation near $20 billion AUD, Cochlear offers both stability and strong accessibility for those seeking exposure to innovative and resilient Australian healthcare names.

FAQ

What is the latest dividend for Cochlear stock?

Cochlear currently pays a dividend, with the most recent annual dividend set at $4.30 AUD per share. The dividend was paid following the company’s 2024 financial year-end and reflects a stable distribution policy. Cochlear’s dividends are fully franked, offering added benefit for Australian investors through the local imputation tax system.

What is the forecast for Cochlear stock in 2025, 2026, and 2027?

Based on the latest available price, the end-of-year forecasts are $391.81 AUD for 2025, $452.09 AUD for 2026, and $602.78 AUD for 2027. This outlook reflects ongoing sector momentum, sustained demand for medical devices, and Cochlear’s strong market leadership in hearing solutions.

Should I sell my Cochlear shares?

Holding onto Cochlear shares may be attractive given its solid growth track record, robust balance sheet, and world-leading position in hearing implant technology. The company’s steady cash flow, regular dividends, and ongoing innovation support its resilience over the medium- to long-term. Given these fundamentals, many investors see value in maintaining their exposure.

How are dividends and capital gains from Cochlear taxed in Australia?

Dividends from Cochlear are fully franked, providing shareholders with tax credits for corporate tax already paid by the company. Capital gains realized on share sales are subject to Australian capital gains tax, with potential discounts if assets are held for more than 12 months. This tax regime increases efficiency for resident investors in Australian stocks like Cochlear.

What is the latest dividend for Cochlear stock?

Cochlear currently pays a dividend, with the most recent annual dividend set at $4.30 AUD per share. The dividend was paid following the company’s 2024 financial year-end and reflects a stable distribution policy. Cochlear’s dividends are fully franked, offering added benefit for Australian investors through the local imputation tax system.

What is the forecast for Cochlear stock in 2025, 2026, and 2027?

Based on the latest available price, the end-of-year forecasts are $391.81 AUD for 2025, $452.09 AUD for 2026, and $602.78 AUD for 2027. This outlook reflects ongoing sector momentum, sustained demand for medical devices, and Cochlear’s strong market leadership in hearing solutions.

Should I sell my Cochlear shares?

Holding onto Cochlear shares may be attractive given its solid growth track record, robust balance sheet, and world-leading position in hearing implant technology. The company’s steady cash flow, regular dividends, and ongoing innovation support its resilience over the medium- to long-term. Given these fundamentals, many investors see value in maintaining their exposure.

How are dividends and capital gains from Cochlear taxed in Australia?

Dividends from Cochlear are fully franked, providing shareholders with tax credits for corporate tax already paid by the company. Capital gains realized on share sales are subject to Australian capital gains tax, with potential discounts if assets are held for more than 12 months. This tax regime increases efficiency for resident investors in Australian stocks like Cochlear.

P. Laurore
P. Laurore
Finance expert
HelloSafe
Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.

Ask a question, an expert will answer